You are on page 1of 44

OBSERVATION & RESULTS

OBSERVATIONS

The observations and results of the clinical study have been given below in
demographic profiles in tabular forms.

Table No. :4.1 Registered patients wise distribution of Raktapradara (N=60)

Number of Patients
Total
Group A Group B
Register 30 30 60
Completed 30 30 60
N= Total number of patients in trial and control group.

Total 30 patients were registered in group A, 30 patients had completed the


treatment. In group B, 30 patients had completed the treatment. Hence, the total
number of patients were 60 for the present study, so observation and results of 60
patients were given below.

Table No.: 4.2 Age wise distribution of patients

Number of Patients
Age group Group A Group B Total %
15-25 Year 5 5 10 16.7
26-35 Year 14 15 29 48.3
36-45 Year 11 10 21 35
Total 30 30 60 100
It was found that maximum number of patients i.e. 16.7% belonged to age
group of 15-25 years, followed by 48.3% patients to 26-35 years and 35% patients to
36-45years.

INCIDENCE OF AGE GROUP


Number of Patients Group A Number of Patients Group B Number of Patients Total

60

29 30 30
15 21
10 14 11 10
5 5

15-25 Year 26-35 Year 36-45 Year Total

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 70
OBSERVATION & RESULTS

Table No.: 4.3 Occupation wise distribution of patients

Number of Patients
Occupation Total %
Group A Group B
Teacher 5 4 9 15
Student 2 1 3 5
Anganwadi 1 1 2 3.33
Asha Worker 1 1 2 3.33
Nurse 1 1 2 3.33
Office clerk 1 2 3 5
Labour 1 3 4 6.67
shopkeeper 2 0 2 3.33
House wife 16 17 33 55
TOTAL 30 30 60 100

On considering the nature of occupation, it was found that 15% parients were
teachers,5 % were students,3.3% were anganwadi worker, 3.3% were asha
worker,3.3% were nurse,5% were office clerk , 6.6% were labourer , 3.3% were
shopkeeper , and 55% were house wife.

OCCUPATION OF PATIENTS
Group A Group B Total
60

33 3030

1617
9
54 213 112 112 112 123 134 202

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 71
OBSERVATION & RESULTS

Table No. :4.4 Socio-economical status wise distribution of patients

ECONOMICAL Number of Patients


STATUS Group A Group B Total %
POOR 6 5 11 18.33
MIDDLE 20 21 41 68.33
RICH 4 4 8 13.33
TOTAL 30 30 60 100

Table revealed that maximum number of patients i.e.68.3% belongs to middle


class family and 18.3% belonged to poor class and 13.3% belonged to rich class
families.

SOCIOECONOMICAL STATUS
Group A Group B Total
60

41
30 30
20 21
11 8
6 5 4 4

POOR MIDDLE RICH TOTAL

Table No.:4.5 Family history wise distribution of patients

FAMILY HISTORY Number of Patients %


Group A Group B Total
Positive 4 5 9 15
Negative 26 25 51 85
TOTAL 30 30 60 100

Table revealed that maximum number of patients i.e.85% belongs to negative


family history and 15% belonged to positive family history .

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 72
OBSERVATION & RESULTS

80
60
Positive
40
Negetive
20
TOTAL
0
Group A Group B Total

Table No. : 4.6 Educational status wise distribution of patients

Number of Patients
Education Total %
Group A Group B
ILLITERATE 4 7 11 18.3
PRIMARY 11 10 21 35
HIGH SCHOOL 8 5 13 21.7
COLLEGE 7 8 15 25
TOTAL 30 30 60 100

It has been observed from above table 18.3% patients were illiterate,35 %
patients were education of primary school ,21.7% patients were education of high
school and rest 25 % patients were education of college.

EDUCATIONAL STATUS
60
Group A Group B Total
21 30 30
4 7 11 11 10 8 5 13 7 8 15

ILLITERATE PRIMARY HIGH SCHOOL COLLEGE TOTAL

Table No. : 4.7 Marital status wise distribution of patients

MARITAL Number of Patients


Total %
STATUS Group A Group B
MARRIED 27 29 56 93.3
UNMARRIED 3 1 4 6.7
TOTAL 30 30 60 100

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 73
OBSERVATION & RESULTS

Above table show that maximum 93.3 % patients were married and 6.7% were
unmarried.

MARITAL STATUS
MARRIED UNMARRIED TOTAL

56 60
27 30 29 30
3 1 4

Group A Group B Total

Table No. : 4.8 Age of menarche wise distribution of patients

MENARCHE Number of Patients


Total %
YEAR Group A Group B
11-12 Year 6 8 14 23.33
13-14 Year 20 21 41 68.33
>14 Year 4 1 5 8.33
Total 30 30 60 100
On considering the data of menarche, maximum number of patients i.e. 68.3 %
were having 13 to 14 years, while 8.3% were having menarche of >14years and 23.3%
were having menarche of 11-12 years.

MENARCHE AGE
Group A Group B Total

60
41
30 30
20 21
6 8 14 4 5
1

11-12 Year 13-14 Year >14 Year Total

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 74
OBSERVATION & RESULTS

Table No.:4.9 Intermenstrual period wise distribution of patients

INTERMENSTRUAL Number of Patients


Total %
PERIOD Group A Group B
26-28 days 8 9 17 28.33
28-30days 14 16 30 50
30-32days 5 3 8 13.33
>33 days 3 2 5 8.33
Total 30 30 60 100
Among 60 patients,50 % were having 28-30 days interval, 13.3% were having
30-32 days interval, 28.3% were having 26-28 days and 8.3 % patients were >33 days
of intermenstrual period.

INTERMENSTRUAL PERIOD
Group A Group B Total
60

30 30 30
17 14 16
8 9 5 3 8 3 2 5

26-28 days 28-30days 30-320days >33 days Total

Table No.: 4.10 Duration of menstrual bleeding wise distribution of patients

Duration of menstrual Number of Patients


Total %
bleeding Group A Group B
<5 days 1 2 3 5
6-7days 5 4 9 15
8-9days 6 10 16 26.7
>9 days 18 14 32 53.3
Total 30 30 60 100
It is evident from the above data, maximum i.e.53% patients were having >9
days , while 26.7% had 8-9 days, 15% had normal duration of menstrual bleeding 6-7
days, and 5% had less than 5 days.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 75
OBSERVATION & RESULTS

DURATION OF BLEEDING
Group A Group B Total
60

32 30 30
16 18 14
5 4 9 6 10
1 2 3

<5 days 6-7days 8-9days >9 days Total

Table No. : 4.11 Amount of menstrual blood loss wise distribution of patients

Amount of menstrual Number of Patients


Total %
blood loss Group A Group B
Scanty 0 1 1 1.6
Moderate 9 10 19 31.7
Excessive 21 19 40 66.7
Total 30 30 60 100

On considering the amount of menstrual blood loss, it was reported that


maximum i.e.66.7% patients had Excessive flow, 31.7% patients had moderate flow
and 1.6% had Scanty blood flow.

AMOUNT OF BLOOD LOSS


Group A Group B Total

60

40
30 30
19 21 19
9 10
0 1 1

Scanty Moderate Excessive Total

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 76
OBSERVATION & RESULTS

Table No.: 4.12 Regularity of menstrual cycle wise distribution of patients

Number of Patients
MENSTRUAL CYCLE Total %
Group A Group B
Regular 29 28 57 95
Irregular 1 2 3 5
Total 30 30 60 100

According to the data 95% patients were having regular menstrual cycle and
rest of 5% were irregular menstrual cycle.

REGULARITY
Regular Irregular Total

57 60

29 30 28 30

1 2 3

Group A Group B Total

Table No. : 4.13 Amount of menstrual blood wise distribution of patients

Number of Patients
AMOUNT Total %
Group A Group B
1-2Pads 1 2 3 5
3-4Pads 3 1 4 6.666666667
5-6Pads 8 10 18 30
>7Pads 18 17 35 58.33333333
Total 30 30 60 100

On considering the amount of menstrual blood loss in the cycle, 5% were


using 1-2 pads, 6.6% were using 3-4 pads, 30% were using 5- 6 pads and 58%were
using more than 7 pads.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 77
OBSERVATION & RESULTS

AMOUNT
Group A Group B Total
60

35 30 30
18 18 17
3 1 4 8 10
1 2 3

1-2Pads 3-4Pads 5-6Pads >7Pads Total

Table No. : 4.14 Odour of menstrual blood wise distribution of patients

Number of Patients
ODOUR Total %
Group A Group B
Foul 2 3 5 8.3
No foul 28 27 55 91.7
TOTAL 30 30 60 100
According to the data 8.3% patients have foul smell present and 91.7%
patients having no foul smell.

ODOUR
Foul No foul TOTAL

55 60
28 30 27 30
2 3 5

Group A Group B Total

Table No. : 4.15 Colour of menstrual blood wise distribution of patients

Number of Patients
Colour Total %
Group A Group B
Red 23 24 47 78.3
Dark red 4 2 6 10
Black 3 4 7 11.7
Total 30 30 60 100

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 78
OBSERVATION & RESULTS

According to the data, 78.3 % patients have Red in colour, 10% patients
having Dark red in colour, 11.7% having Black in colour.

COLOUR
Group A Group B Total
60
47

30 30
23 24

4 6 4 7
2 3

Red Dark red Black Total

Table No. : 4.16 Nature of menstrual blood wise distribution of patients

Number of Patients
NATURE Total %
Group A Group B
With Clot 8 6 14 23.3
Without clot 22 24 46 76.7
TOTAL 30 30 60 100

According to the data, 23.3% patients were having nature of menstruation with
clots and 76.7% patients having without clots.

NATURE
Clot Without clot TOTAL
60
46
30 30
22 24
14
8 6

Group A Group B Total

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 79
OBSERVATION & RESULTS

Table No. :4.17 Body build wise distribution of patients

Number of Patients
BODY BUILT Group A Group B Total %
Average 19 18 37 61.7
Thin 6 5 11 18.3
Obese 5 7 12 20
TOTAL 30 30 60 100
Above table highlights that maximum i.e.61.7 % patients had average, 18.3 %
had thin and 20 % patients had obese body build.

BODY BUILT
60
Group A Group B Total

37
30 30
19 18
11 12
6 5 5 7

Average Thin Obese TOTAL

Table No. :4.18 Bowel habit wise distribution of patients

Number of Patients
BOWEL HABIT Group A Group B Total %
Regular 12 13 25 41.77
Irregular 9 8 17 28.3
Constipative 9 9 18 30
TOTAL 30 30 60 100

It has been observed from above table maximum no. of patients were regular
bowel habit that is 41.7%,28.3% patients were irregular bowel habit and rest 30%
patients were constipative bowel habit.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 80
OBSERVATION & RESULTS

BOWEL HABIT
Group A Group B Total 60
25 30 30
12 13 9 8 17 9 9 18

Regular Irregular Costipative TOTAL

Table No. : 4.19 Prakriti wise distribution of patients

Number of Patients
Prakriti Total %
Group A Group B
Vata-Pitta 22 21 43 71.6
Pitta-Kapha 5 8 13 21.7
Vata-Kapha 3 1 4 6.7
Total 30 30 60 100
Above highlighted that maximum i.e 71.6% patients had vata-pitta
prakriti,21.7% had pitta-kapha prakriti and only 6.7 % patients had vata-kapha
prakriti.

PRAKRITI 60

43 Group A Group B Total


30 30
22 21
13
5 8
3 1 4

Vata-Pitta Pitta-Kapha Vata-Kapha Total

Table No. : 4.20 Pallor wise distribution of patients

Number of Patients
PALLOR Total %
Group A Group B
Mild 19 18 37 61.6
Moderate 7 8 15 25
Severe 0 1 1 1.7
Absent 4 3 7 11.7
Total 30 30 60 100

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 81
OBSERVATION & RESULTS

Data reviled maximum number of patients i.e. 61.6% were of Mild pallor,
while 25 % were Moderate pallor 11.7% were absent in pallor and minimum numbers
of patient 1.7% were severe pallor condition.

PALLOR 60

Group A Group B Total


37
30 30
19 18
15
7 8 7
1 1 4 3
0

Mild Moderate Severe Absent Total

Table No. : 4.21 Nutritional status wise distribution of patients

NUTRITIONAL Number of Patients


STATUS Group A Group B Total %
Good 14 15 29 48.3
Average 12 14 26 43.3
Poor 4 1 5 8.4
TOTAL 30 30 60 100

It has been observed from 48.3% patients had good nutrition,43 % patients had

average nutrition and only 8.4 % patients had poor nutrition.

NUTRITIONAL 60

Group A Group B Total

29 30 30
26
14 15 12 14
4 5
1

Good Average Poor TOTAL

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 82
OBSERVATION & RESULTS

Table No. : 4.22 Diet habit wise distribution of patients

Number of Patients
Diet Total %
Group A Group B
Vegetarians 7 5 12 20
Mixed 23 25 48 80
TOTAL 30 30 60 100

Above data shows that maximum patients were i.e. 80% mixed diet while 20%
were vegetarians.

DIET HABIT
60
Vegetarian Mixed TOTAL
48

30 30
23 25

12
7 5

Group A Group B Total

Table No. : 4.23 Appetite wise distribution of patients

Number of Patients
APPETITE Total %
Group A Group B
Poor 12 13 25 58.3
Good 18 17 35 41.7
TOTAL 30 30 60 100

It was found that maximum i.e. 58.3% of patients were good appetite and
41.7% were poor appetite of the patients.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 83
OBSERVATION & RESULTS

APPETITE 60

Poor Good TOTAL


35
30 30
25
18 17
12 13

Group A Group B Total

Table No.: 4.24 Habitat wise distribution of patients

Number of Patients
Habitat Total
Group A Group B %
Urban 16 18 34 56.7
Rural 14 12 26 43.3
Total 30 30 60 100

The data of the present series shows that the majority of the patients 56.7%
were from urban and 43.3% from rural areas.

HABITAT
60
Urban Rural Total

34
26
16 18
14 12

Group A Group B Total

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 84
OBSERVATION & RESULTS

Table No.: 4.25 Obstetric History wise distribution of patients

Number of Patients
OBSTETRIC HISTORY Total %
Group A Group B
Nullipara 3 5 8 14.28
Parity Primipara 7 5 12 21.42
Multipara 17 19 36 64.28
TOTAL 27 29 56 100
1 6 8 14 29.2
No. of life birth 2 14 16 30 62.5
3 3 1 4 8.3
TOTAL 23 25 48 100
History of
Abortion Present 6 4 10 17.85
Absent 21 25 46 82.14
TOTAL 27 29 56 100
F.T.N.D 17 10 27 56.3
Mode of delivery
F.T.C.S 9 12 21 43.7
TOTAL 26 22 48 100
UNMARRIED 3 1 4 100

Maximum numbers of patients i.e. 64.2%,while 21.4% patients had primipara,


only 14.2% patients had no obstetric history and 4% patients were unmarried.

Maximum number of patient i.e 62.5% were 2 live birth, 29.2% patients had 1
live birth and 8.3% patients were 3 live birth in these 14% patients had no obstetric
history and 4% patients were unmarried.

Maximum numbers of patients i.e. 82.1% had negative history of abortion,


while 17.85 % had positive history of abortion, and 4% patients were unmarried.

Maximum numbers of patients i.e.56.3% had F.T.N.D history of mode of


delivery, while 43.7% had F.T.C.S history of mode of delivery and 4% patients were
unmarried.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 85
OBSERVATION & RESULTS

Table No.: 4.26 Type of contraception wise distribution table

Number of Patients
Contraceptive Total %
Group A Group B
Temporary 17 18 35 58.3
Permanent 10 11 21 35
Unmarried 3 1 4 6.7
Total 30 30 60 100

Maximum numbers of patients i.e.58.3% had using temporary method of


contraception, while 35% had using permanent method of contraception and 6.7%
patients were unmarried.

CONTRACEPTIVE
Group A Group B Total

60

35
30 30
17 18 21
10 11
3 1 4

Temporary Permanent Unmarried Total

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 86
OBSERVATION & RESULTS

Table No.: 4.27 PER SPECULUM (P/S) EXAMINATION WISE


DISTRIBUTION OF 56 MARRIED PATIENTS OF RAKTAPRADARA.

Number of Patients
PER SPECULUM
Group Total %
EXAMINATION Group A
B
Vulvitis & Present 0 0 0 0
Vaginitis Absent 27 29 56 100
TOTAL 27 29 56 100
Nil 21 23 44 78.57
Watery 5 4 9 16.07
Vaginal discharge
Curdy 1 2 3 5.35
Yellowish 0 0 0 0
TOTAL 27 29 56 100
Normal 25 28 53 94.6
Cervix Cervicitis 2 1 3 5.4
Erosion 0 0 0 0
TOTAL 27 29 56 100
Parous 17 16 33 59
External OS
Nulliparous 10 13 23 41
TOTAL 27 29 56 100

All the patients i.e. 100% were having no vulvitis vaginits. 78.5% patients
were having no vaginal discharge, 16% were having watery vaginal discharge, 5.3%
patients were having curdy vaginal discharge. 94.6% patients were having normal
cervix, while 5.4 % patients were having cervicitis. 59% patients were having parous
os and 41% patients had nuiliparous os.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 87
OBSERVATION & RESULTS

Table No.: 4.28 PER VAGINAL (P/V) EXAMINATION WISE DISTRIBUTION


OF 56 MARRIED PATIENTS OF RAKTAPRADARA.

PER VAGINAL Number of Patients


Total %
EXAMINATION Group A Group B
AV,AF 25 26 51 91
Uterus position
RV,RF 2 3 5 9
TOTAL 27 29 56 100
Normal 11 15 26 46.42
Uterus size
Bulky 16 14 30 53.6
TOTAL 27 29 56 100
Mobile 27 29 56 100
Uterus mobility
Immobile 0 0 0 0
TOTAL 27 29 56 100
Hard 1 2 3 5.4
Cervix Consistency
Normal 26 27 53 94.6
TOTAL 27 29 56 100
Normal 26 27 53 94.6
Fornices
Tenderness 1 2 3 5.4
TOTAL 27 29 56 100
Painfull 3 4 7 12.5
Movement
Painless 24 25 49 87.5
TOTAL 27 29 56 100

In gynaecological per vaginal examination shows that 91% patients were


having the position of uterus antiverted, antiflexed followed by 9 % were having
uterus retroverted ,retroflexed. In total 56 patients 46.4% had normal size of uterus,
while 53.6% patients had bulky uterus. In p/v. Examination of cervix, consistency of
cervix was observed normal in 94.6% patients while 5.4% patients cervix was
observed hard. In 94.6% patients having fornices were observed normal, while 5.4%
patients were observed tender fornices. In per vaginal examination of movement of
uterus, 87.5% patients having painless movement of uterus, while 12.5% patients
having painful movement of uterus.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 88
OBSERVATION & RESULTS

Table No. : 4.29 Percentage of patients got improvement with respect to Clinical
features, in Trial group & Control group (N1=30)

PERCENTAGE OF PATIENTS IMPROVED


After 1st cycle After 2nd After 3rd
CLINICAL FEATURES of cycle of cycle of
Treatment Treatment Treatment

TG% CG% TG% CG% TG% CG%


AMOUNT OF BLOOD
LOSS 67 87 90 100 97 100
DURATION OF BLOOD
FLOW 43 63 90 97 100 100
CONSISTENCY OF
BLEEDING 57 63 83 87 87 97
BODY ACHE 53 63 90 90 100 100
PALLOR 50 50 90 67 97 83

N1 - Total number of patients in trial group.

N2-Total number of patients in control group.

From above table number - 4.28 It has been observed that regarding amount of
blood loss 67 % of patient in trial group and 87% of patients in control group got
improved after treatment of 1st cycle , after 2nd cycle of treatment 90% patients in
trial group and 100% patients in control group got improvement. After 3rd cycle of
treatment 97% patients in trial group and 100% patients in control group got
improvement.

Regarding duration of blood flow it has been observed that after 1st cycle of
treatment 43% patients in trial group and 63% patients in control group got
improvement. After 2nd cycle of treatment 90% patients in trial group and 97%
patients in control group got improved. After 3rd cycle of treatment 100% patients in
trial group and 100% patients in control group got improvement.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 89
OBSERVATION & RESULTS

Regarding consistency of bleeding it has been observed that after treatment of


1st cycle 57% patients in trial group and 63% patients in control group got
improvement. After 2nd cycle of treatment 83%patients in trail group and 87%
patients in control group got improvement. After 3rd cycle of treatment 87% patients
in trial group and 97% patients in control group got improvement .

Regarding body ache it has been observed that after treatment of 1st cycle
53% patients in trial group and 63% patients in control group got improvement. After
2nd cycle of treatment 90%patients in trail group and 90% patients in control group
got improvement. After 3rd cycle of treatment 100% patients in trial group and 100%
patients in control group got improvement .

Regarding pallor it has been observed that after treatment of 1st cycle 50%
patients in trial group and 50% patients in control group got improvement. After 2nd
cycle of treatment 90%patients in trail group and 67% patients in control group got
improvement. After 3rd cycle of treatment 97% patients in trial group and 87%
patients in control group got improvement .

PERCENTAGE OF PATIENTS IMPROVED AFTER 1ST MENSRTUAL CYCLE

% OF PATIENTS IMPROVEMENT A.T. OF 1 ST CYCLE


AT1 TG% AT1 CG%
87
67 63 63 63
57 53 50 50
43

AMOUNT OF BLOOD
DURATION
LOSS OF BLOOD
CONSISTENCY
FLOW OF BLEEDONG
BODY ACHE PALLOR

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 90
OBSERVATION & RESULTS

PERCENTAGE OF PATIENTS IMPROVED AFTER 2ND MENSRTUAL CYCLE

% OF IMPROVEMENT A.T. OF 2ND CYCLE


AT2 TG% AT2 CG%
100
90 90 97 83 87 90 90 90
67

AMOUNT OF BLOOD
DURATION
LOSSOF BLOOD
CONSISTENCY
FLOW OF BLEEDONG
BODY ACHE PALLOR

PERCENTAGE OF PATIENTS IMPROVED AFTER 3RD MENSRTUAL CYCLE

% OF IMPROVEMENT A.T. OF 3RD CYCLE


AT3 TG% AT3 CG%
97 100 100 100 97 100 100 97
87 83

AMOUNT OF DURATION OF CONSISTENCY BODY ACHE PALLOR


BLOOD LOSS BLOOD FLOW OF BLEEDONG

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 91
OBSERVATION & RESULTS

Table No. : 4.30 Average percentage of change (Improvement ) in Clinical


features, in Trial group & Control group (N1=30, N2=30)

AVERAGE % OF CHANGE ( IMPROVEMENT) W.R. TO CLINICAL


FEATURES
After 1st After 2nd After 3rd
cycle of cycle of cycle of
CLINICAL FEATURES
Treatment Treatment Treatment
TG% CG% TG% CG% TG% CG%
AMOUNT OF BLOOD
LOSS 30.00 34.44 38.65 54.44 62.78 65
DURATION OF BLOOD
FLOW 15.00 25.00 30.62 55.56 62.22 64.4
CONSISTENCY OF
BLEEDONG 27.78 28.89 33.24 51.67 62.78 66.1
BODY ACHE 50.00 27.78 35.07 52.78 61.67 65.6
PALLOR 22.78 21.11 38.52 33.33 62.22 45

N1-Total number patients in trial group,

N2- Total number of patients in control group

From above table no-.4.29 it has been observed that regarding amount of
blood loss 30% cured in trial group and 34.44% cured in control group after 1st cycle
of treatment. After 2nd cycle of treatment 38.65 % in trial group & 55.44% in control
group has been cured. After 3rd cycle of treatment 62.78% cured in trial group and
65% cured in control group.

Regarding duration of blood flow it has been observed that 15% cured in trial
group & 30.62% cured in control group after 1st cycle of treatment. After 2nd cycle of
treatment 30.62% cured in trial group & 55.56% cured in control group. After 3rd
cycle of treatment 62.22% cured in trial group & 64.4% cured in control group.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 92
OBSERVATION & RESULTS

Regarding consistency of bleeding it has been observed that 27.78% cured in


trial group & 28.89% cured in control group after 1st cycle of treatment. After 2nd
cycle of treatment 33.24% cured in trial group & 51.67% cured in control group. After
3rd cycle of treatment 62.78% cured in trial group & 66.1% cured in control group.

Regarding body ache it has been observed that 50% cured in trial group &
27.78% cured in control group after 1st cycle of treatment. After 2nd cycle of
treatment 35% cured in trial group & 52.78% cured in control group. After 3rd cycle
of treatment 61.67% cured in trial group & 65.6% cured in control group.

Regarding pallor it has been observed that 22.78% cured in trial group &
21.11% cured in control group after 1st cycle of treatment. After 2nd cycle of
treatment 38.52% cured in trial group & 33.33% cured in control group. After 3rd
cycle of treatment 62.22% cured in trial group & 45% cured in control group.

AVERAGE % OF CHANGE ( IMPROVEMENT) W.R. TO CLINICAL


FEATURESAFTER 1ST MENSTRUAL CYCLE

AVERAGE CHANGE AFTER TREATMENT OF 1ST


CYCLE
AT1 TG% AT1 CG%
50.00

34.44
30.00 25.00 27.78 28.89 27.78
22.78 21.11
15.00

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 93
OBSERVATION & RESULTS

AVERAGE % OF CHANGE ( IMPROVEMENT) W.R. TO CLINICAL


FEATURESAFTER 2ND MENSTRUAL CYCLE

AVERAGE OF CHANGE AFTER TREATMENT 2ND


CYCLE
AT2 TG% AT2 CG%

54.44 55.56 52.78


51.67
38.52 33.33
33.24 35.07
28.65 30.62

AMOUNT OF BLOOD
DURATION
LOSS OF BLOOD
CONSISTENCY
FLOW OF BLEEDONG
BODY ACHE PALLOR

AVERAGE % OF CHANGE ( IMPROVEMENT) W.R. TO CLINICAL


FEATURESAFTER 3RD MENSTRUAL CYCLE

AVERAGE CHANGE OF AFTER TREATMENT OF 3RD


CYCLE
AT3 TG% AT3 CG%

62.7 65 62.264.4 62.866.1 61.765.6 62.2


45

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 94
OBSERVATION & RESULTS

Table No.4.31 Distribution of cases according to severity of clinical features,


before and after treatment of trial group.(N = 30)

TRIAL GROUP
After 1st After 2nd After 3rd
Before
cycle of cycle of cycle of
CLINICAL Treatment
Treatment Treatment Treatment
FEATURES
G G G G G G G G G G G G G G G G
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
AMOUNT OF
0
BLOOD LOSS 3 14 13 2 7 20 1 4 18 8 0 7 20 3 0
DURATION
OF BLOOD
FLOW 0 3 11 16 0 4 22 4 2 19 9 0 7 21 2 0
CONSISTENC
Y OF 1
BLEEDING 1 7 11 11 5 9 12 4 7 16 7 0 2 15 3 0
BODY ACHE 0 2 17 11 1 9 16 4 4 17 8 1 7 22 1 0
1
PALLOR 1 0 21 8 1 1 14 4 5 17 8 0 9 18 3 0
N1= Total number of patients in trial group

For amount of blood loss out of 30 patients before treatment in trial group
maximum number i.e. 14patients were in G2, 13 patients in G3 and 3 patients were
G1. After 1st cycle of treatment it was observed that 2 patients were in G0 7 patients
were in G1 20 patients were in G2 and 1 patient were in G3. After 2nd cycle of
treatment it was observed that 4 patients were in G0,18 patients were inG1 ,8 patients
were in G2 and no patient were in G3 . After 3rd cycle of treatment it was observed
that 07 patients were in G0 , 20 patients were in G1,3 patients were in G2 and no
patient were G3.

For duration of blood flow, before treatment in trial group 3 patients were in
G1,11 patients were in G2 and 16 patients were in G3. After 1st cycle of treatment it
was observed that 04 patients were in G1,22 patients were in G2 and rest 4 patients
were in G3. After 2nd cycle of treatment it was observed that 19 patients were in G1,9

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 95
OBSERVATION & RESULTS

patients were inG2 and 02 patients were in G0. After 3rd cycle of treatment 7 patients
were in G0, 21 patients were in G1 and 02 patients were in G2.

For consistency of bleeding, before treatment in trial group 1 patients were in


G0,7 patients were in G1,11 patients were in G2 and 11 patients were in G3. After
1st cycle of treatment it was observed that 05 patients were in G0, 9 patients were in
G1,12 patients were in G2 and rest 4 patients were in G3. After 2nd cycle of treatment
it was observed that 7 patients were in G0,16 patients were in G1 and 07 patients were
in G2. After 3rd cycle of treatment 12 patients were in G0, 15 patients were in G1 and
03 patients were in G2.

For body ache, before treatment in trial group 2 patients were in G1,17
patients were in G2, and 11 patients were in G3 . After 1st cycle of treatment it was
observed that 01 patients were in G0, 9 patients were in G1,16 patients were in G2 and
rest 4 patients were in G3. After 2nd cycle of treatment it was observed that 4 patients
were in G0,17 patients were in G1, 08 patients were in G2 and 1 patient were in G3.
After 3rd cycle of treatment 7 patients were in G0, 22 patients were in G1 and 01
patients were in G2.

For pallor, before treatment in trial group 1patient were in G0,no patients
were in G1,21 patients were in G2, and 8 patients were in G3 . After 1st cycle of
treatment it was observed that 01 patients were in G0, 11 patients were in G1,14
patients were in G2 and rest 4 patients were in G3. After 2nd cycle of treatment it was
observed that 5 patients were in G0,17 patients were in G1, 08 patients were in G2 and
no patient were in G3. After 3rd cycle of treatment 9 patients were in G0, 18 patients
were in G1 and 03 patients were in G2.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 96
OBSERVATION & RESULTS

Table No. 4.32 Distribution of cases according to severity of clinical features,


before and after treatment of control group.(N = 30)

CONTROL GROUP
After 1st cycle After 2nd After 3rd
Before of cycle of cycle of
CLINICAL
Treatment Treatment Treatment Treatment
FEATURES
G G G G G G G G G G G GG G G
1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
AMOUNT OF
BLOOD LOSS 0 11 19 0 7 23 0 2 21 7 0 5 23 2 0
DURATION OF
BLOOD FLOW 2 16 12 0 9 21 0 3 22 5 0 6 23 1 0
CONSISTENCY
OF BLEEDONG 3 19 8 1 12 17 0 5 18 7 0 9 20 1 0
BODY ACHE 0 21 9 0 12 16 2 4 20 5 1 7 22 1 0
1
PALLOR 3 19 8 0 11 18 1 0 19 1 0 0 27 3 0

N1= Total number of patients in control group

For amount of blood loss out of 30 patients before treatment in control group
i.e. 11patients were in G2, 19 patients in G3 and no patients were in G1. After 1st
cycle of treatment it was observed that 7 patients were in G1, 23 patients were in G2
and no patient were in G3. After 2nd cycle of treatment it was observed that 2
patients were in G0,21 patients were inG1 ,7 patients were in G2 and no patient were
in G3 . After 3rd cycle of treatment it was observed that 05 patients were in G0 , 23
patients were in G1,2 patients were in G2 and no patient were G3.

For duration of blood flow, before treatment in control group 2 patients were
in G1,16 patients were in G2 and 12 patients were in G3. After 1st cycle of treatment
it was observed that 09 patients were in G1 and 21 patients were in G2. After 2nd
cycle of treatment it was observed that 03 patients were in G0, 22 patients were in G1

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 97
OBSERVATION & RESULTS

and 5 patients were inG2. After 3rd cycle of treatment 6 patients were in G0, 23
patients were in G1 and 01 patient were in G2.

For consistency of bleeding, before treatment in control group 3 patients


were in G1,19 patients were in G2 and 8 patients were in G3. After 1st cycle of
treatment it was observed that 01 patient were in G0, 12 patients were in G1 and 17
patients were in G2. After 2nd cycle of treatment it was observed that 5 patients were
in G0,18 patients were in G1 and 07 patients were in G2. After 3rd cycle of treatment
9 patients were in G0, 20 patients were in G1 and 01 patient were in G2.

For body ache, before treatment in control group 21 patients were in G2 and 9
patients were in G3 . After 1st cycle of treatment it was observed that 12 patients
were in G1,16 patients were in G2 and rest 2 patients were in G3. After 2nd cycle of
treatment it was observed that 4 patients were in G0,20 patients were in G1, 05
patients were in G2 and 1 patient were in G3. After 3rd cycle of treatment 7 patients
were in G0, 22 patients were in G1 and 01 patients were in G2.

For pallor, before treatment in control group 3 patients were in G1, 19 patients
were in G2, and 8 patients were in G3 . After 1st cycle of treatment it was observed
that 11 patients were in G1,18 patients were in G2 and rest 1 patient were in G3. After
2nd cycle of treatment it was observed that 19 patients were in G1, 11 patients were in
G2 and no patient were in G3. After 3rd cycle of treatment 27 patients were in G1
and 03 patients were in G2.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 98
OBSERVATION & RESULTS

TABLE NO.: 4.33 CLINICAL ASSESSMENT OF RESULT OF TRIAL GROUP


& CONTROL GROUP (N=60)

AT1 AT2 AT3


CLINICAL
GR-T GR-C GR-T GR-C GR-T GR-C
ASSESSMENT
F % F % F % F % F % F %

UNSATISF 1 36. 36.6


11 2 6.67 0 0.00 1 3.33 0 0.00
ACTORY 1 6 7
1 60.0 1 43.3 1 46.6 16.6
60 18 5 2 6.67
MILD 8 0 3 3 4 7 7
3.3 1 1 53.3 1 60.0 2 86.6
1 1 3.33 50.0
MODERATE 3 5 6 3 8 0 6 7
MAXIMUM 0 0.0 0 0.00 0 0.00 0 0.00 6 20.0 2 6.67
TOTAL 0 0.0 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00
T.G- TRIAL GROUP

C.G- CONTROL GROUP

f= frequency, %=percentage, N=number of patients.

N.B. Above the analysis has been made from all the clinical features.

Clinical assessment based on the percentage improvement was depending


upon the clinical features of the disease i.e. cure= 100%, maximum improvement=
75% - 99%, moderate improvement=50% - 74%, mild improvement= 25% - 49% and
unsatisfactory=0 to 24%.

Figure no. shows that, from the clinical analysis out of 30 patients in trial
group after 1st menstrual cycle of treatment 11(36.67%) were got unsatisfactory
result, 18(60%) were got mild improvement, 1(3.33%) were got moderate
improvement and no patients having maximum and total cured.

In control group out of 30 patients 11(36.67%) were got unsatisfactory result


and 18(60%) were got mild improvement and 1(3.33%) patients having moderate, no
patient got maximum and total cured.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 99
OBSERVATION & RESULTS

Figure no.... shows that, from the clinical analysis out of 30 patients in trial
group after 2nd menstrual cycle treatment 2(6.67%) were got unsatisfactory result,
13(43.33%) were got mild improvement, 15(50%) were got moderate improvement,
no patient were got maximum improvement and total cured.

In control group out of 12 patients no patients having unsatisfactory result and


5(41.67%) were got mild improvement, 7(58.33%) were got moderate improvement
and no patients having maximum and total cured.

Figure no....shows that, from the clinical analysis out of 30 patients in trial
group after 3rd menstrual cycle of treatment 1(3.33%) patients having unsatisfactory
result, 5(16.67%) were got mild improvement, 18(60%) were got moderate
improvement and 6(20%) were got maximum improvement and no patients were total
cured.

In control group out of 30 patients no patients having unsatisfactory


result,2(6.67%) mild improvement, 26(86.67%) were got moderate improvement,
2(6.67%) were got maximum and no patients having total cured.

90
80
70
60
50
UNSATISFACTORY
40
MILD
30
MODERATE
20
10 MAXIMUM

0 TOTAL
% % % % % %

TG% CG TG CG TG CG

AT1 AT2 AT3

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 100
OBSERVATION & RESULTS

Table No .:- 4.34 Statistical analysis showing the effectiveness of the trial&
control group to clinical features after treatment

Clinical Mean t-
Mean±SD d.f. p-value Remark

Group
features Diff±SD value

BT
2.33±0.66
AT1 1.66±0.661 0.667±0.479 29 7.62 <0.001 ***
AT2 1.133±0.629 1.2±0.61 29 10.80 <0.001 ***
GROUP T
AMOUNT OF BLOOD LOSS

AT3 0.867±0.571 1.47±0.68 29 11.80 <0.001 ***

BT 2.63±0.49
AT1 1.76±0.43 0.9±0.43 29 4.23 <0.001 ***
AT2 1.16±0.53 1.43±0.5 29 4.84 <0.001 ***
GROUP C

AT3 0.9±0.48 1.73±0.64 29 10.83 <0.001 ***

BT 2.43±.679
AT1 2±0.525 0.43±0.5 29 4.71 < 0.001 ***
DURATION OF BLOOD FLOW

AT2 1.23±0.568 1.2±0.61 29 10.77 < 0.001 ***


GROUP T

AT3 0.83±0.53 1.6±0.86 29 10.2 < 0.001 ***

BT 2.33±0.60
AT1 1.7±0.46 0.63±0.49 29 5.29 <0.001 ***
AT2 1.06±0.521 1.26±0.521 29 8.43 <0.001 ***
GROUP C

AT3 0.83±0.46 1.5±0.63 29 6.37 <0.001 ***

BT 2.067±0.868
AT1 1.5±0.94 0.6±0.5 29 6.20 < 0.001 ***
CONSISTENCY OF BLEEDING

AT2 1±0.69 1.07±0.64 29 9.13 < 0.001 ***


GROUP T

AT3 0.7±0.65 1.37±0.85 29 8.80 < 0.001 ***

BT 2.16±0.59
AT1 1.53±0.57 0.6±0.5 29 5.30 <0.001 ***
AT2 1.07±0.64 1.1±0.61 29 4.81 <0.001 ***
GROUP C

AT3 0.73±0.52 1.43±0.63 29 6.29 <0.001 ***

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 101
OBSERVATION & RESULTS

BT 2.3±0.6
AT1 1.77±0.73 0.53±0.51 29 5.76 < 0.001 ***
AT2 1.2±0.71 1.1±0.5 29 11.00 < 0.001 ***
GROUP T
AT3 0.8±0.48 1.47±0.63 29 12.80 < 0.001 ***

BT 2.3±0.47
AT1 1.66±0.60 0.63±0.49 29 1.29 >0.05 *
BODY ACHE

AT2 1.1±0.66 0.6±0.6 29 4 <0.001 ***


GROUP C

AT3 0.8±0.48 1.5±0.51 29 2.95 <0.005 **

BT 2.1±0.6
AT1 1.7±0.75 1.43±5.23 29 3.81 <0.001 ***
AT2 1.1±0.66 2.03±5.123 29 4.50 <0.001 ***
GROUP T

AT3 0.8±0.61 2.33±5.26 29 3.79 <0.001 ***

BT 2.2±0.6
AT1 1.66±0.54 0.5±0.50 29 5.3 <0.001 ***
AT2 1.37±0.49 0.8±0.66 29 3.82 <0.001 ***
GROUP C
PALLOR

AT3 1.1±0.30 1.07±0.64 29 1.67 >0.05 *

* >0.05 SIGNIFICANT AT 5% LEVEL


** <0.005 SIGNIFICANT AT 1% LEVEL
*** <0.001 HIGHLY SIGNIFICANT AT 0.1% LEVEL

For statistical analysis we have compared mean ± SD before treatment of each


clinical features findings with after treatment of both trial and control group.

AMOUNT OF BLOOD LOSS

Statistical analysis shows that in case of Amount of blood loss the mean ± SD
before treatment was 2.33±0.66 which reduced to 1.66±0.66, 1.133±0.629,
0.86±0.57after 1st, 2nd, and 3rd menstrual cycle of treatment in trial group
respectively. The test of significance shows that the trial drug is effective to reduce
this symptom with P value <0.001 which is highly significant.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 102
OBSERVATION & RESULTS

In control group it shows that the mean ± SD before treatment was 2.3±0.47
which reduced to 1.66±0.60, 1.1±0.66, and 0.8±0.48 after 1st, 2nd, and 3rd menstrual
cycle of treatment respectively. The test of significance shows that the control drug is
effective to reduce this symptom with P value <0.001 which is highly significant .

2.5

1.5 GROUP T
GROUP C
1

0.5

0
BT AT1 AT2 AT3

DURATION OF BLOOD FLOW

Statistical analysis shows that in case of duration of blood flow the mean ± SD
before treatment was 2.43±.67 which reduced to 2±0.52, 1.23±0.56 and 0.83±0.53
after 1st, 2nd, and 3rd menstrual cycle of treatment in trial group respectively. The test
of significance shows that the trial drug is effective to reduce this symptom with P
value <0.001 which is highly significant.

In control group it shows that the mean ± SD before treatment was 2.33±0.60
which reduced to 1.7±0.46, 1.06±0.52, and 0.83±0.46 after 1st, 2nd, and 3rd menstrual
cycle of treatment respectively. The test of significance shows that the control drug is
effective to reduce this symptom with P value <0.001 which is highly significant .

2
GROUP T
1
GROUP C
0
BT AT1 AT2 AT3

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 103
OBSERVATION & RESULTS

CONSISTENCY OF BLEEDING

Statistical analysis shows that in case of consistency of bleeding the mean ±


SD before treatment was 2.06±0.86 which reduced to 1.5±0.94, 1±0.69 and 0.7±0.65
after 1st, 2nd, and 3rd menstrual cycle of treatment in trial group respectively. The test
of significance shows that the trial drug is effective to reduce this symptom with P
value <0.001 which is highly significant.

In control group it shows that the mean ± SD before treatment was 2.16±0.59
which reduced to 1.53±0.57, 1.07±0.64, and 0.73±0.52 after 1st, 2nd, and 3rd
menstrual cycle of treatment respectively. The test of significance shows that the
control drug is effective to reduce this symptom with P value <0.001 which is highly
significant .

2.5
2
1.5
GROUP T
1
0.5 GROUP C
0
BT AT1 AT2 AT3

BODY ACHE

Statistical analysis shows that in case of body ache the mean ± SD before
treatment was 2.3±0.6 which reduced to 1.77±0.73, 1.2±0.71 and 0.8±0.48 after 1st,
2nd, and 3rd menstrual cycle of treatment in trial group respectively. The test of
significance shows that the trial drug is effective to reduce this symptom with P value
<0.001 which is highly significant.

In control group it shows that the mean ± SD before treatment was 2.3±0.47
which reduced to 1.66±0.60 after 1st menstrual cycle of treatment the test of
significance shows that the control drug is effective to reduce this symptom with P
value >0.05 which is significant at 5% level , 1.1±0.66 after 2nd menstrual cycle of
treatment the test of significance shows that the control drug is effective to reduce this
symptom with P value <0.001 which is highly significant , and 0.8±0.48 after 3rd
menstrual cycle of treatment the test of significance shows that the control drug is
effective to reduce this symptom with P value <0.05 which is significant in 1% level .

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 104
OBSERVATION & RESULTS

2
GROUP T
1
GROUP C
0
BT AT1 AT2 AT3

PALLOR

Statistical analysis shows that in case of pallor the mean ± SD before treatment
was 2.1±0.6 which reduced to 1.7±0.75, 1.1±0.66 and 0.8±0.61 after 1st, 2nd, and 3rd
menstrual cycle of treatment in trial group respectively. The test of significance shows
that the trial drug is effective to reduce this symptom with P value <0.001 which is
highly significant.

In control group it shows that the mean ± SD before treatment was 2.2±0.6
which reduced to 1.66±0.54 and 1.37±0.49 after 1st & 2nd menstrual cycle the test of
significance shows that the control drug is effective to reduce this symptom with P
value <0.001 which is highly significant . After 3rd menstrual cycle of treatment the
mean ± SD 1.1±0.30 the test of significance shows that the control drug is effective to
reduce this symptom with P value >0.05 which is significant at 5% level .

2.5
2
1.5
GROUP T
1
GROUP C
0.5
0
BT AT1 AT2 AT3

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 105
OBSERVATION & RESULTS

Table No .:- 4.35 Statistical analysis showing the effectiveness of the trial&
control group to Clinical features after treatment

Gro
Clinical features Mean Diff±SD d.f. t-value p-value Remark

up
T 0.66±0.47
AT1 58 1.67 > 0.05 *
C 0.9±0.43
CONSISTENCY OF BLEEDING DURATION OF BLOOD FLOW AMOUNT OF BLOOD LOSS

T 1.2±0.61
AT2 58 1.09 > 0.05 *
C 1.43±0.5
T 1.47±0.68
AT3 58 1.14 > 0.05 *
C 1.73±0.64

T 0.43±0.5
AT1 58 1.17 > 0.05 *
C 0.63±0.49
T 1.2±0.61
AT2 58 0.60 >0.05 *
C 1.26±0.521
T 1.6±0.86
AT3 58 0.64 > 0.05 *
C 1.5±0.63

T 0.6±0.5
AT1 58 0.72 > 0.05 *
C 0.6±0.5
T 1.07±0.64
AT2 58 0.29 > 0.05 *
C 1.1±0.61
T 1.37±0.85
AT3 58 0.43 > 0.05 *
C 1.43±0.63

T 0.53±0.51
AT1 58 1.23 > 0.050 *
C 0.63±0.49
T 1.1±0.5
BODY ACHE

AT2 58 1.40 > 0.050 *


C 0.6±0.6
T 1.47±0.63
AT3 58 0.29 > 0.050 *
C 1.5±0.51

T 0.5±0.50
AT1 58 0.60 > 0.050 *
C 0.5±0.50
PALLOR

T 1.1±0.548
AT2 58 3.00 <0.005 **
C 0.8±0.66
T 1.4±0.62
AT3 58 1.16 > 0.05 *
C 1.07±0.64

* > 0.05INSIGNIFICANT AT 5% LEVEL


** < 0.005SIGNIFICANT AT 1% LEVEL

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 106
OBSERVATION & RESULTS

AMOUNT OF BLOOD LOSS

Statistical analysis of trial group as compare to control group in case of


amount of blood loss after lst menstrual cycle of treatment the mean difference ± SD
was 0.66±0.47 in TG and 1.2±0.61in CG. The test of significance shows that there is
no significant difference between TG and CG with p value >0.05.

After 2nd menstrual cycle of treatment the mean difference ± SD was 1.2±0.61
in TG and 1.43 ±0.5 in CG. The test of significance shows that there is no significant
difference between TG and CG with p value >0.05.

After 3rd menstrual cycle of treatment the mean difference ± SD was


1.47±0.68in TG and 1.73±0.64in CG. The test of significance shows that there is no
significant difference between TG and CG with p value >0.05.

2
GROUP T
1
GROUP C

0
BT AT1 AT2 AT3

DURATION OF BLOOD FLOW


Statistical analysis of trial group as compare to control group in case of
duration of blood flow after lst menstrual cycle of treatment the mean difference ± SD
was 0.43±0.5 in TG and 0.63±0.49 CG. The test of significance shows that there is no
significant difference between TG and CG with p value >0.05.

After 2nd menstrual cycle of treatment the mean difference ± SD was 1.2±0.61
in TG and 1.26±0.52 in CG. The test of significance shows that there is no significant
difference between TG and CG with p value >0.05.

After 3rd menstrual cycle of treatment the mean difference ± SD was 1.6±0.86
in TG and 1.5±0.63 in CG. The test of significance shows that there is no significant
difference between TG and CG with p value >0.05.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 107
OBSERVATION & RESULTS

2
GROUP T
1
GROUP C
0
BT AT1 AT2 AT3

CONSISTENCY OF BLEEDING

Statistical analysis of trial group as compare to control group in case of


consistency of bleeding after lst menstrual cycle of treatment the mean difference ±
SD was 0.6±0.5 in TG and 0.6±0.5 CG. The test of significance shows that there is no
significant difference between TG and CG with p value >0.05.

After 2nd menstrual cycle of treatment the mean difference ± SD was


1.07±0.64 in TG and 1.1±0.61 in CG. The test of significance shows that there is no
significant difference between TG and CG with p value >0.05.

After 3rd menstrual cycle of treatment the mean difference ± SD was


1.37±0.85 in TG and 1.43±0.63 in CG. The test of significance shows that there is no
significant difference between TG and CG with p value >0.05.

2.5
2
1.5
GROUP T
1
0.5 GROUP C
0
BT AT1 AT2 AT3

BODY ACHE

Statistical analysis of trial group as compare to control group in case of


consistency of bleeding after lst menstrual cycle of treatment the mean difference ±
SD was 0.53±0.51 in TG and 0.63±0.49 CG. The test of significance shows that there
is no significant difference between TG and CG with p value >0.05.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 108
OBSERVATION & RESULTS

After 2nd menstrual cycle of treatment the mean difference ± SD was 1.1±0.5
in TG and 0.6±0.6 in CG. The test of significance shows that there is no significant
difference between TG and CG with p value >0.05.

After 3rd menstrual cycle of treatment the mean difference ± SD was


1.47±0.63 in TG and 1.5±0.51 in CG. The test of significance shows that there is no
significant difference between TG and CG with p value >0.05.

2.5
2
1.5
GROUP T
1
0.5 GROUP C
0
BT AT1 AT2 AT3

PALLOR

Statistical analysis of trial group as compare to control group in case of pallor


after lst menstrual cycle of treatment the mean difference ± SD was 0.5±0.5 in TG and
0.5±0.5 CG. The test of significance shows that there is no significant difference
between TG and CG with p value >0.05.

After 2nd menstrual cycle of treatment the mean difference ± SD was 1.1±0.54
in TG and 0.8±0.66 in CG. The test of significance shows that there is significant
difference between TG and CG with p value <0.005.

After 3rd menstrual cycle of treatment the mean difference ± SD was 1.4±0.62
in TG and 1.07±0.64 in CG. The test of significance shows that there is no significant
difference between TG and CG with p value >0.05.

2.5
2
1.5
GROUP T
1
0.5 GROUP C
0
BT AT1 AT2 AT3

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 109
OBSERVATION & RESULTS

Table No :-4.36 EFFECT OF THERAPY ON HAEMATOLOGICAL


PARAMETERS IN TRIAL GROUP & CONTROL GROUP.

clinical Mean t- p-
Group

Mean±SD d.f. Remark


features Diff±SD value value
BT 9.69±1.02
AT 10.74±0.68 1.04±0.53 29 10.74 <0.001 ***
TG

BT 9.24±0.65
Hb%

AT 10.18±1.77 0.93±1.70 29 3.9 <0.001 ***


CG

BT 6910±1248.8
AT 6283±1139.5 626.6±1126.7 29 3.04 <0.001 ***
TG

BT 7656±1018
TLC

AT 7123±1438 533±1398 29 9.34 <0.001 ***


CG

BT 240166±66494
PLATELET

AT 225666±66640 14500±17633 29 4.50 <0.001 ***


TG
COUNT

BT 228200±46412
AT 222833±55548 5366±56637 29 11 <0.001 ***
CG

BT 13.9±4.47
AT 11.5±3.30 2.43±3.09 29 2 >0.05 ***
TG

BT 9.73±3.81
ESR

AT 7±3.05 2.73±1.92 29 1.1 >0.05 ***


CG

BT 1.25±0.23
BLEEDING

AT 1.26±0.18 00±0.23 29 0.12 >0.05 **


TG

BT 1.35±0.31
TIME

AT 1.43±0.29 0.08±0.27 29 1.6 >0.05 **


CG

BT 2.21±0.34
CLOTTING

AT 2.16±0.31 0.04±0.3 29 0.79 >0.05 **


TG

BT 2.31±0.33
TIME

AT 2.43±0.28 0.12±0.33 29 2.05 >0.05 **


CG

** <0.05 SIGNIFICANT AT 1% LEVEL


*** <0.001 HIGHLY SIGNIFICANT AT 0.1%
LEVEL

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 110
OBSERVATION & RESULTS

Statistical analysis shows trial group and control group that in case of Hb% tes
the mean ± SD before treatment was 9.69±1.02 which increased to 10.74±0.68 after
treatment. The test of significance shows that the trial drug is effective to reduce this
symptom with P value <0.001 which is highly significant.

In control group it shows that the mean ± SD before treatment was 9.24±0.65
which increased to 10.18±1.77after of treatment the test of significance shows that the
control drug is effective to reduce this symptom with P value <0.001 which is highly
significant.

25
20
15
GROUP C
10
GROUP T
5
0
BT AT

Statistical analysis shows trial group and control group that in case of TLC test
the mean ± SD before treatment was 6910±1248.8 which increased to 6283±1139.5
after treatment. The test of significance shows that the trial drug is effective to reduce
this symptom with P value <0.001 which is highly significant.

In control group it shows that the mean ± SD before treatment was 7656±1018
which increased to 7123±1438 after of treatment the test of significance shows that
the control drug is effective to reduce this symptom with P value <0.001 which is
highly significant.
10000
8000
6000
GROUP T
4000
GROUP C
2000
0
BT AT

Statistical analysis shows trial group and control group that in case of platelet
count test the mean ± SD before treatment was 240166±66494 which increased to

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 111
OBSERVATION & RESULTS

225666±66640 after treatment. The test of significance shows that the trial drug is
effective to reduce this symptom with P value <0.001 which is highly significant.

In control group it shows that the mean ± SD before treatment was


228200±46412 which increased to 222833±55548 after of treatment the test of
significance shows that the control drug is effective to reduce this symptom with P
value <0.001 which is highly significant.

250000
240000
230000 GROUP T
220000 GROUP C
210000
BT AT

Statistical analysis shows trial group and control group that in case of ESR test
the mean ± SD before treatment was 13.9±4.47 which increased to 11.5±3.30 after
treatment. The test of significance shows that the trial drug is effective to reduce this
symptom with P value >0.05which is little change of significant.

In control group it shows that the mean ± SD before treatment was


9.73±3.81which increased to 7±3.05 after of treatment the test of significance shows
that the control drug is effective to reduce this symptom with P value >0.05which is
little change of significant.

15

10
GROUP T
5
GROUP C
0
BT AT

Statistical analysis shows trial group and control group that in case of
bleeding time test the mean ± SD before treatment was 1.25±0.23which increased to
1.26±0.18 after treatment. The test of significance shows that the trial drug is effective
to little changes with P value >0.05 which is not significant.

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 112
OBSERVATION & RESULTS

In control group it shows that the mean ± SD before treatment was 1.35±0.31
which increased to 1.43±0.29 after of treatment the test of significance shows that the
control drug is effective to little changes with P value >0.05 which is not significant.

1.5
1.4
1.3 GROUP T
1.2 GROUP C
1.1
BT AT

Statistical analysis shows trial group and control group that in case of clotting
time test the mean ± SD before treatment was 2.21±0.34 which increased to
2.16±0.31 after treatment. The test of significance shows that the trial drug is effective
to little changes with P value >0.05 which is not significant.

In control group it shows that the mean ± SD before treatment was 2.31±0.33
which increased to 2.43±0.28 after of treatment the test of significance shows that the
control drug is effective to little changes with P value >0.05 which is not significant.

2.5
2.4
2.3
GROUP T
2.2
GROUP C
2.1
2
BT AT

"A CLINICAL STUDY ON RAKTAPRADARA AND ITS MANAGEMENT WITH DHATRYADI CHURNA" Page 113